Sleep disruption in the intensive care unit (ICU) is a common comorbidity associated with
patient morbidity and distress. There are no recommended pharmacologic interventions for
sleep promotion, and many pharmacologic solutions may actually increase the risk of adverse
outcomes rather than impart benefits. Gabapentin, an anticonvulsant with applications in
neuropathic pain, has been investigated for sleep promotion in various populations of
outpatients. Here investigators propose a pilot study of gabapentin as a therapy for sleep
disruption in the ICU. Outcomes measured will be sleep quality as measured by RCSQ
(Richards-Campbell Sleep Questionnaire), wrist actigraphy, EEG, and BIS monitoring. The goal
is to enroll 80 critically ill patients, 40 intubated and 40 non-intubated patients. The
study will take place over 2 nights, with baseline sleep measurements occurring on the first
night and gabapentin administration with repeat sleep measurements on the second night.